Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
Crinetics Pharmaceuticals, Inc.
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
June 2, 2026
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
May 22, 2026
Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
May 7, 2026
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
April 27, 2026
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
April 8, 2026
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
February 6, 2026
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
January 26, 2026
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
January 22, 2026